Aura Biosciences (AURA) Cash from Investing Activities (2020 - 2026)

Aura Biosciences' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $54.9 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 84.14% year-over-year to $54.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.7 million (down 32.0% YoY) and the FY2025 annual result came in at $35.6 million, down 48.28% from the prior year.
• Cash from Investing Activities was $54.9 million for Q1 2026 at Aura Biosciences, up from $29.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $54.9 million in Q1 2026 and bottomed at -$90.1 million in Q4 2023.
• A 5-year average of -$1.3 million and a median of $17.9 million in 2022 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 3231.94% in 2022, while the deepest fall reached 35812.68% in 2022.
• Aura Biosciences' Cash from Investing Activities stood at -$16.9 million in 2022, then sank by 434.01% to -$90.1 million in 2023, then surged by 132.95% to $29.7 million in 2024, then increased by 0.43% to $29.8 million in 2025, then surged by 84.07% to $54.9 million in 2026.
• Business Quant data shows AURA's Cash from Investing Activities at $54.9 million in Q1 2026, $29.8 million in Q4 2025, and -$44.0 million in Q3 2025.